Metsera, Inc. (NASDAQ:MTSR – Get Free Report) reached a new 52-week high on Monday . The stock traded as high as $31.64 and last traded at $30.19, with a volume of 5601 shares traded. The stock had previously closed at $29.50.
Metsera Stock Performance
Metsera Company Profile
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Read More
- Five stocks we like better than Metsera
- What Are Dividend Challengers?
- Merck: 4 No-Brainer Reasons to Buy This Dip
- Stock Market Sectors: What Are They and How Many Are There?
- Ackman Announces Major Stake in Uber: Should You Follow His Lead?
- Why Are These Companies Considered Blue Chips?
- Wells Fargo Upgraded These 3 Stocks—Here’s Why They Stand Out
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
